查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529828

生物製药监管事务外包市场规模、份额、趋势分析报告：按服务、按阶段、按模式、按阶段/服务、按模式/服务、按地区、细分市场预测，2024-2030年

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

生物製药监管事务外包市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球生物製药监管事务外包市场规模将达到36.9亿美元，2024年至2030年复合年增长率为8.87%，预计将创历史新高。

生物製药公司的全球化是推动整体市场需求的主要成长要素之一。亚太地区、拉丁美洲、中东和非洲的新兴市场提供较低的产品开发和製造成本、税收优惠、相对低成本的技术纯熟劳工以及支持性法规。上述因素使得该区域市场对于生物製药公司在外包和业务扩张方面具有诱人的前景，从而刺激了对监管服务的需求。此外，新兴国家中 EMA 和/或 FDA 许可设施的存在预计将增加该国的外国投资，并增加对法律代表和监管咨询服务等监管服务的需求。

新兴国家进行的临床试验数量大幅增加。这是由于与美国等新兴经济体相比，能够以相对较低的成本获得熟练劳动力、先进技术和基础设施，并且这些地区能够获得临床试验提交和产品註册等监管服务，因此需求旺盛。 。新兴国家占全球临床试验申请总数的30.0%以上，预计未来几年这一份额将持续增加，进而促进市场成长。

一些生物製药公司专注于核心能力，并将非核心职能外包，以提高生产力和业务效率。这些公司在遵守国际法规方面面临多项挑战，这可能是一个漫长而乏味的过程。因此，按照可实现的时间表和合理的成本将新分子推向市场的竞赛可能会推动对服务提供者的需求。此外，许多不具备内部能力的中小型生物製药公司倾向于将业务外包，预计这将对行业的进步产生积极影响。

生物相似药、孤儿药、个人化药物和适应性试验设计等市场的成长预计将推动这些领域监管业务的需求。随着公司向新领域扩张，对具有监管经验且需要遵守法规的熟练服务供应商的需求不断增长。特别是在新兴经济体，政府的支持显着增加了孤儿药的发展。 Simrect、 Vectibix、 Mircera和 Kineret 等生技药品的专利到期正在增加生物相似药的需求和开发，从而促进了该领域监管服务的需求。

生物製药监管事务外包市场报告亮点

  • 2023 年，监管写作和出版领域占据最大的市场占有率。此细分市场的高速成长是由于生技药品日益复杂，需要准确和全面的文件、严格的全球监管要求（需要彻底提交）以及需要专业知识来确保合规性等。基因治疗和生物仿製药等生技药品创新的快速步伐，需要不断变化的法规的最新知识，预计将推动整体市场的成长。
  • 2023年，製药公司业务收益占有率最大，超过76.23%。该细分市场的成长是由大量生技药品临床试验、不断增加的 ATMP产品平臺、更严格的先进疗法监管指南以及临床试验、资料管理和监管合规等非核心业务外包趋势推动的这些因素有助于进一步推动该领域的成长。
  • 单株抗体 (mAb) 领域在 2023 年占据最大的销售份额。此细分市场的成长归因于单株抗体技术的快速进步，包括新的递送方法和治疗靶点，需要现代而精确的监管策略，从而带来整体市场的成长潜力。
  • 2023 年，北美市场占据主导地位，份额为 30.54%。该地区的市场成长得益于大量的研发活动和政府对临床试验的承诺。此外，生物製药公司和外包服务供应商的强大存在也是预计推动市场成长的主要因素。例如，2021年10月，美国FDA核准了11项新的临床试验研究，将在未来四年内提供超过2,500万美元的资金，用于支持治疗罕见疾病的创新药物的开发。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 生物製药监理事务外包市场的变数、趋势与范围

  • 市场体系展望
  • 市场动态
  • 技术进步
  • 定价模式分析
  • 2023 年临床试验数量分析
  • 生物製药监管事务外包市场：分析工具
  • COVID-19 影响分析

第四章生物製药监理事务外包市场：按服务分类的估计与趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析

第五章生物製药监理事务外包市场：分阶段估算及趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析

第六章生物製药监理事务外包市场：依模态估算及趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析
  • 单株抗体 (mAb)
  • 重组蛋白
  • 疫苗
  • 细胞/基因治疗
  • 生物相似药
  • 其他的

第七章 生物製药监管事务外包市场：分阶段和服务的估计和趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析

第八章生物製药监管事务外包市场：分阶段和模式的估计和趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析

第九章生物製药监管事务外包市场：按模式和服务进行估算和趋势分析

  • 细分仪表板
  • 全球生物製药业务外包市场波动分析
  • 2018-2030年全球生物製药监理业务外包市场规模及趋势分析

第十章生医监理事务外包市场：区域估算及趋势分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 2018 年至 2030 年市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018 年至 2030 年市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018 年至 2030 年市场估计与预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018 年至 2030 年市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018 年至 2030 年市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十一章竞争格局

  • 市场参与企业分类
  • 竞争市场占有率：依产业分类（2023 年）
  • 竞争地图：依服务分类 (2023)
  • 服务热图分析
  • 公司简介
    • Lonza AG
    • Wuxi Apptec Inc.
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Freyrsolutions
    • Catalent Inc.
    • Piramal Group
    • AGC Biologics
    • ICON Plc.
    • Charles River Laboratories International, Inc.
    • Labcorp
    • Parexel International
    • Medpace Holdings, Inc.
    • IQVIA
    • Syneos Health
    • SGS SA (SGS)
Product Code: GVR-4-68040-369-4

Biologics Regulatory Affairs Outsourcing Market Growth & Trends:

The global biologics regulatory affairs outsourcing market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 8.87% from 2024 to 2030, according to a new report by Grand View Research, Inc. Globalization of biopharmaceutical companies is one of the major growth drivers boosting overall market demand. Emerging markets of Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical companies, thereby stimulating the demand for regulatory services. Furthermore, the presence of EMA- and/or FDA-approved facilities in emerging economies is anticipated to increase foreign investments in the country and the demand for regulatory services, such as legal representation and regulatory consulting services.

A significant increase has been witnessed in the number of clinical trials conducted in emerging economies. This can be attributed to the availability of skilled labor, advanced technologies, and infrastructure facilities at relatively lower costs than developed economies such as the U.S., which is expected to stimulate the demand for regulatory services such as clinical trial applications & product registrations in these regions. Emerging economies contribute to more than 30.0% of total clinical trial applications submitted across the globe, and the share is expected to increase over the coming years, contributing to market growth.

Several biopharmaceutical companies are focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies face several challenges with regard to complying with global regulations, which can be a lengthy and tedious process. Thus, the race to launch a novel molecule in the market in a feasible timeline and at a reasonable cost will likely propel the demand for service providers. Furthermore, many small- and medium-scale biopharma companies lacking in-house capabilities are inclined towards outsourcing regulatory affairs, which is estimated to positively influence the industry's progression.

Growth in markets for biosimilars, orphan drugs, personalized medicines, adaptive trial designs, and others is projected to boost the demand for regulatory specialization in these areas. As several companies expand into new avenues, the increasing need for skilled service providers with experience in regulations leads to the necessity to comply with regulations. Government support, especially in developed economies, has significantly increased the development of orphan drugs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services in this segment.

Biologics Regulatory Affairs Outsourcing Market Report Highlights:

  • The regulatory writing & publishing segment held the largest market share in 2023. The high segment growth is owing to the increasing complexity of biologics requiring precise and comprehensive documentation, stringent global regulatory requirements demanding thorough submissions, and the need for specialized expertise to ensure compliance. The rapid pace of innovation in biologics, such as gene therapies and biosimilars, necessitates up-to-date knowledge of evolving regulations is anticipated overall market growth
  • The pharmaceutical companies segment accounted for the largest revenue share of over 76.23% in 2023. The segmental growth is owing to a high number of clinical trials for biologics, a growing product pipeline for ATMPs, stringent regulatory guidelines for advanced therapeutics, and growing outsourcing trends for non-core activities such as clinical trials, data management, regulatory compliance etc., are few factors further boosting segment growth
  • The monoclonal antibodies (mAbs) segment accounted for the largest revenue share in 2023. The segmental growth is owing to rapid advancements in mAb technology, including novel delivery methods and therapeutic targets, which require updated and precise regulatory strategies leading to overall market growth potential
  • North America dominated the market with a share of 30.54% in 2023. The regional market growth is owing to high R&D activities and government initiatives for clinical trials. Moreover, the strong presence of biopharmaceutical companies and outsourcing service providers is another major factor expected to propel market growth. For instance, in October 2021, the U.S. FDA approved 11 novel clinical trial research, resulting in over USD 25 million in funding over the next four years to support the development of innovative drugs to treat rare diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1:
    • 1.10.2. Objective - 2:
    • 1.10.3. Objective - 3:
    • 1.10.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service Outlook
    • 2.2.2. Phase Outlook
    • 2.2.3. Modality Outlook
    • 2.2.4. Phase by Service Outlook
    • 2.2.5. Phase by Modality Outlook
    • 2.2.6. Modality by Service Outlook
    • 2.2.7. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Biologics Regulatory Affairs Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Number of Clinical Trials
      • 3.2.1.2. Increasing Adoption of the Personalized Medicine and Novel Therapeutics
      • 3.2.1.3. Rising R&D Investment in the Healthcare Industry
      • 3.2.1.4. Advancements in the Regulatory Affairs Market
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Managing Relationships
  • 3.3. Technological Advancements
    • 3.3.1. Existing and Emerging Use of Technology and Preferred Tools
    • 3.3.2. Differentiating In-House Tools Vs Widely Available
    • 3.3.3. Key Technology Pillars
      • 3.3.3.1. Digital Transformation and Data Integrity
      • 3.3.3.2. Artificial Intelligence, Machine Learning/Automation
      • 3.3.3.3. Data Analysis and Predictive Modeling
      • 3.3.3.4. Automation of Routine Tasks
      • 3.3.3.5. Compliance Monitoring
      • 3.3.3.6. Discovery and Development
      • 3.3.3.7. Regulatory Guidelines Related to AI/ML
    • 3.3.4. Big Data and Analytics
    • 3.3.5. RTP, Text Processing and Analytics
    • 3.3.6. Speech and Video Analytics
    • 3.3.7. IoT (Internet Of Things)
    • 3.3.8. AI Tools
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Biologics Regulatory Affairs Outsourcing Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Biologics Regulatory Affairs Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 4.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
    • 4.3.1. Regulatory Consulting
      • 4.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.2. Strategy & Development Planning
      • 4.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.3. QA Consulting
      • 4.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.4. Agent Services
      • 4.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 4.3.1.5. Others
      • 4.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.2. Legal Representation
      • 4.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.3. Regulatory Writing & Publishing
      • 4.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.4. Product Registration & Clinical Trial Applications
      • 4.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.5. Regulatory Submissions
      • 4.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.6. Regulatory Operations
      • 4.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 4.3.7. Other Services
      • 4.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biologics Regulatory Affairs Outsourcing Market: Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 5.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
    • 5.3.1. Preclinical
      • 5.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 5.3.2. Clinical
      • 5.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.2. Phase I
      • 5.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.3. Phase II
      • 5.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.4. Phase III
      • 5.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 5.3.2.5. Phase IV
      • 5.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biologics Regulatory Affairs Outsourcing Market: Modality Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 6.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
  • 6.4. Monoclonal Antibodies (mAbs)
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Recombinant Proteins
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Vaccines
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.7. Cell & Gene Therapies
    • 6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.8. Biosimilars
    • 6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biologics Regulatory Affairs Outsourcing Market: Phase by Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 7.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Service, 2018 to 2030 (USD Million)
    • 7.3.1. Preclinical
      • 7.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.2. Regulatory Consulting
      • 7.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.3. Legal Representation
      • 7.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.4. Regulatory Writing & Publishing
      • 7.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.5. Product Registration & Clinical Trial Applications
      • 7.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.6. Regulatory Submissions
      • 7.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.7. Regulatory Operations
      • 7.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.1.8. Other Services
      • 7.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.3.2. Clinical
      • 7.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.2. Regulatory Consulting
      • 7.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.3. Legal Representation
      • 7.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.4. Regulatory Writing & Publishing
      • 7.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.5. Product Registration & Clinical Trial Applications
      • 7.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.6. Regulatory Submissions
      • 7.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.7. Regulatory Operations
      • 7.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 7.3.2.8. Other Services
      • 7.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Biologics Regulatory Affairs Outsourcing Market: Phase by Modality Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 8.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Modality, 2018 to 2030 (USD Million)
    • 8.3.1. Preclinical
      • 8.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.2. Monoclonal Antibodies (mAbs)
      • 8.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.3. Recombinant Proteins
      • 8.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.4. Vaccines
      • 8.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.5. Cell & Gene Therapies
      • 8.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.6. Biosimilars
      • 8.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.1.7. Others
      • 8.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.3.2. Clinical
      • 8.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.2. Monoclonal Antibodies (mAbs)
      • 8.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.3. Recombinant Proteins
      • 8.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.4. Vaccines
      • 8.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.5. Cell & Gene Therapies
      • 8.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.6. Biosimilars
      • 8.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 8.3.2.7. Others
      • 8.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Biologics Regulatory Affairs Outsourcing Market: Modality by Service Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 9.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Modality by Service, 2018 to 2030 (USD Million)
    • 9.3.1. Monoclonal Antibodies (mAbs)
      • 9.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.2. Regulatory Consulting
      • 9.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.3. Legal Representation
      • 9.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.4. Regulatory Writing & Publishing
      • 9.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.5. Product Registration & Clinical Trial Applications
      • 9.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.6. Regulatory Submissions
      • 9.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.7. Regulatory Operations
      • 9.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.1.8. Other Services
      • 9.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.2. Recombinant Proteins
      • 9.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.2. Regulatory Consulting
      • 9.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.3. Legal Representation
      • 9.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.4. Regulatory Writing & Publishing
      • 9.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.5. Product Registration & Clinical Trial Applications
      • 9.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.6. Regulatory Submissions
      • 9.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.7. Regulatory Operations
      • 9.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.2.8. Other Services
      • 9.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.3. Vaccines
      • 9.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.2. Regulatory Consulting
      • 9.3.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.3. Legal Representation
      • 9.3.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.4. Regulatory Writing & Publishing
      • 9.3.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.5. Product Registration & Clinical Trial Applications
      • 9.3.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.6. Regulatory Submissions
      • 9.3.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.7. Regulatory Operations
      • 9.3.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.3.8. Other Services
      • 9.3.3.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.4. Cell & Gene Therapies
      • 9.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.2. Regulatory Consulting
      • 9.3.4.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.3. Legal Representation
      • 9.3.4.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.4. Regulatory Writing & Publishing
      • 9.3.4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.5. Product Registration & Clinical Trial Applications
      • 9.3.4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.6. Regulatory Submissions
      • 9.3.4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.7. Regulatory Operations
      • 9.3.4.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.4.8. Other Services
      • 9.3.4.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.5. Biosimilars
      • 9.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.2. Regulatory Consulting
      • 9.3.5.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.3. Legal Representation
      • 9.3.5.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.4. Regulatory Writing & Publishing
      • 9.3.5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.5. Product Registration & Clinical Trial Applications
      • 9.3.5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.6. Regulatory Submissions
      • 9.3.5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.7. Regulatory Operations
      • 9.3.5.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.5.8. Other Services
      • 9.3.5.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 9.3.6. Others
      • 9.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.2. Regulatory Consulting
      • 9.3.6.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.3. Legal Representation
      • 9.3.6.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.4. Regulatory Writing & Publishing
      • 9.3.6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.5. Product Registration & Clinical Trial Applications
      • 9.3.6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.6. Regulatory Submissions
      • 9.3.6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.7. Regulatory Operations
      • 9.3.6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 9.3.6.8. Other Services
      • 9.3.6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 10. Biologics Regulatory Affairs Outsourcing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Competitive Market share, by Industry (2023)
  • 11.3. Competition Mapping by Service Type (2023)
  • 11.4. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.5. Company Profiles
    • 11.5.1. Lonza AG
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Service Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. Wuxi Apptec Inc.
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Service Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. Thermo Fisher Scientific Inc.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Service Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. Eurofins Scientific SE
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Service Benchmarking
      • 11.5.4.4. Strategic Initiatives
    • 11.5.5. Freyrsolutions
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Service Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. Catalent Inc.
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Service Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. Piramal Group
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Service Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. AGC Biologics
      • 11.5.8.1. Company Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Service Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. ICON Plc.
      • 11.5.9.1. Company Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Service Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. Charles River Laboratories International, Inc.
      • 11.5.10.1. Company Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Service Benchmarking
      • 11.5.10.4. Strategic Initiatives
    • 11.5.11. Labcorp
      • 11.5.11.1. Company Overview
      • 11.5.11.2. Financial Performance
      • 11.5.11.3. Service Benchmarking
      • 11.5.11.4. Strategic Initiatives
    • 11.5.12. Parexel International
      • 11.5.12.1. Company Overview
      • 11.5.12.2. Financial Performance
      • 11.5.12.3. Service Benchmarking
      • 11.5.12.4. Strategic Initiatives
    • 11.5.13. Medpace Holdings, Inc.
      • 11.5.13.1. Company Overview
      • 11.5.13.2. Financial Performance
      • 11.5.13.3. Service Benchmarking
      • 11.5.13.4. Strategic Initiatives
    • 11.5.14. IQVIA
      • 11.5.14.1. Company Overview
      • 11.5.14.2. Financial Performance
      • 11.5.14.3. Service Benchmarking
      • 11.5.14.4. Strategic Initiatives
    • 11.5.15. Syneos Health
      • 11.5.15.1. Company Overview
      • 11.5.15.2. Financial Performance
      • 11.5.15.3. Service Benchmarking
      • 11.5.15.4. Strategic Initiatives
    • 11.5.16. SGS SA (SGS)
      • 11.5.16.1. Company Overview
      • 11.5.16.2. Financial Performance
      • 11.5.16.3. Service Benchmarking
      • 11.5.16.4. Strategic Initiatives

List of Tables

  • 1. List of Secondary Sources
  • 2. List of Abbreviations
  • 3. Global Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 4. Global Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 5. Global Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 6. Global Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 7. Global Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 8. Global Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 9. Global Biologics Regulatory Affairs Outsourcing, by Region, 2018 - 2030 (USD Million)
  • 10. North America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 11. North America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 12. North America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 13. North America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 14. North America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 15. North America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 16. North America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 17. U.S. Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 18. U.S. Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 19. U.S. Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 20. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 21. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 22. U.S. Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 23. Canada Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 24. Canada Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 25. Canada Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 26. Canada Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 27. Canada Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 28. Canada Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 29. Mexico Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 30. Mexico Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 31. Mexico Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 32. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 33. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 34. Mexico Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 35. Europe Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 36. Europe Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 37. Europe Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 38. Europe Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 39. Europe Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 40. Europe Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 41. Europe Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 42. Germany Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 43. Germany Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 44. Germany Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 45. Germany Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 46. Germany Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 47. Germany Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 48. UK Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 49. UK Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 50. UK Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 51. UK Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 52. UK Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 53. UK Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 54. France Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 55. France Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 56. France Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 57. France Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 58. France Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 59. France Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 60. Italy Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 61. Italy Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 62. Italy Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 63. Italy Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 64. Italy Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 65. Italy Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 66. Spain Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 67. Spain Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 68. Spain Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 69. Spain Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 70. Spain Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 71. Spain Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 72. Denmark Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 73. Denmark Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 74. Denmark Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 75. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 76. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 77. Denmark Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 78. Sweden Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 79. Sweden Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 80. Sweden Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 81. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 82. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 83. Sweden Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 84. Norway Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 85. Norway Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 86. Norway Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 87. Norway Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 88. Norway Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 89. Norway Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 90. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 91. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 92. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 93. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 94. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 95. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 96. Asia Pacific Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 97. China Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 98. China Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 99. China Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 100. China Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 101. China Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 102. China Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 103. Japan Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 104. Japan Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 105. Japan Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 106. Japan Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 107. Japan Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 108. Japan Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 109. India Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 110. India Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 111. India Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 112. India Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 113. India Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 114. India Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 115. South Korea Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 116. South Korea Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 117. South Korea Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 118. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 119. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 120. South Korea Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 121. Australia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 122. Australia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 123. Australia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 124. Australia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 125. Australia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 126. Australia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 127. Thailand Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 128. Thailand Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 129. Thailand Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 130. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 131. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 132. Thailand Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 133. Latin America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 134. Latin America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 135. Latin America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 136. Latin America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 137. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 138. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 139. Latin America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 140. Brazil Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 141. Brazil Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 142. Brazil Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 143. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 144. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 145. Brazil Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 146. Argentina Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 147. Argentina Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 148. Argentina Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 149. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 150. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 151. Argentina Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 152. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • 153. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 154. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 155. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 156. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 157. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 158. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 159. South Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 160. South Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 161. South Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 162. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 163. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 164. South Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 165. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 166. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 167. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 168. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 169. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 170. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 171. UAE Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 172. UAE Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 173. UAE Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 174. UAE Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 175. UAE Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 176. UAE Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • 177. Kuwait Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • 178. Kuwait Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • 179. Kuwait Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • 180. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • 181. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • 182. Kuwait Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

List of Figures

  • 1. Information Procurement
  • 2. Primary Research Pattern
  • 3. Market Research Approaches
  • 4. Value Chain-Based Sizing & Forecasting
  • 5. Market Formulation & Validation
  • 6. Biologics Regulatory Affairs Outsourcing, Market Segmentation
  • 7. Market Driver Relevance Analysis (Current & Future Impact)
  • 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • 9. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 10. Porter's Five Forces Analysis
  • 11. Regional Marketplace: Key Takeaways
  • 12. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • 13. Global Biologics Regulatory Affairs Outsourcing, for Strategy & Development Planning, 2018 - 2030 (USD Million)
  • 14. Global Biologics Regulatory Affairs Outsourcing, for QA Consulting, 2018 - 2030 (USD Million)
  • 15. Global Biologics Regulatory Affairs Outsourcing, for Agent Services, 2018 - 2030 (USD Million)
  • 16. Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • 17. Global Biologics Regulatory Affairs Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • 18. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 19. Global Biologics Regulatory Affairs Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 20. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • 21. Global Biologics Regulatory Affairs Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • 22. Global Biologics Regulatory Affairs Outsourcing, for Preclinical, 2018 - 2030 (USD Million)
  • 23. Global Biologics Regulatory Affairs Outsourcing, for Clinical, 2018 - 2030 (USD Million)
  • 24. Global Biologics Regulatory Affairs Outsourcing, for Phase I, 2018 - 2030 (USD Million)
  • 25. Global Biologics Regulatory Affairs Outsourcing, for Phase II, 2018 - 2030 (USD Million)
  • 26. Global Biologics Regulatory Affairs Outsourcing, for Phase III, 2018 - 2030 (USD Million)
  • 27. Global Biologics Regulatory Affairs Outsourcing, for Phase IV, 2018 - 2030 (USD Million)
  • 28. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • 29. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Legal Representation, 2018 - 2030 (USD Million)
  • 30. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 31. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 32. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • 33. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Operations, 2018 - 2030 (USD Million)
  • 34. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Other Services, 2018 - 2030 (USD Million)
  • 35. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • 36. Global Biologics Regulatory Affairs Outsourcing, for Clinical Legal Representation, 2018 - 2030 (USD Million)
  • 37. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 38. Global Biologics Regulatory Affairs Outsourcing, for Clinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 39. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • 40. Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Operations, 2018 - 2030 (USD Million)
  • 41. Global Biologics Regulatory Affairs Outsourcing, for Clinical Other Services, 2018 - 2030 (USD Million)
  • 42. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 43. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • 44. Global Biologics Regulatory Affairs Outsourcing, for Vaccines, 2018 - 2030 (USD Million)
  • 45. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 46. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars, 2018 - 2030 (USD Million)
  • 47. Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • 48. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 49. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • 50. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Vaccines, 2018 - 2030 (USD Million)
  • 51. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 52. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
  • 53. Global Biologics Regulatory Affairs Outsourcing, for Preclinical Others, 2018 - 2030 (USD Million)
  • 54. Global Biologics Regulatory Affairs Outsourcing, for Clinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • 55. Global Biologics Regulatory Affairs Outsourcing, for Clinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • 56. Global Biologics Regulatory Affairs Outsourcing, for Clinical Vaccines, 2018 - 2030 (USD Million)
  • 57. Global Biologics Regulatory Affairs Outsourcing, for Clinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • 58. Global Biologics Regulatory Affairs Outsourcing, for Clinical Biosimilars, 2018 - 2030 (USD Million)
  • 59. Global Biologics Regulatory Affairs Outsourcing, for Clinical Others, 2018 - 2030 (USD Million)
  • 60. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Consulting, 2018 - 2030 (USD Million)
  • 61. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Legal Representation, 2018 - 2030 (USD Million)
  • 62. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 63. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 64. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Submissions, 2018 - 2030 (USD Million)
  • 65. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Operations, 2018 - 2030 (USD Million)
  • 66. Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Other Services, 2018 - 2030 (USD Million)
  • 67. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Consulting, 2018 - 2030 (USD Million)
  • 68. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Legal Representation, 2018 - 2030 (USD Million)
  • 69. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 70. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 71. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Submissions, 2018 - 2030 (USD Million)
  • 72. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Operations, 2018 - 2030 (USD Million)
  • 73. Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Other Services, 2018 - 2030 (USD Million)
  • 74. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Consulting, 2018 - 2030 (USD Million)
  • 75. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Legal Representation, 2018 - 2030 (USD Million)
  • 76. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 77. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 78. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Submissions, 2018 - 2030 (USD Million)
  • 79. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Operations, 2018 - 2030 (USD Million)
  • 80. Global Biologics Regulatory Affairs Outsourcing, for Vaccines Other Services, 2018 - 2030 (USD Million)
  • 81. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Consulting, 2018 - 2030 (USD Million)
  • 82. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Legal Representation, 2018 - 2030 (USD Million)
  • 83. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 84. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 85. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Submissions, 2018 - 2030 (USD Million)
  • 86. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Operations, 2018 - 2030 (USD Million)
  • 87. Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Other Services, 2018 - 2030 (USD Million)
  • 88. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Consulting, 2018 - 2030 (USD Million)
  • 89. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Legal Representation, 2018 - 2030 (USD Million)
  • 90. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 91. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 92. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Submissions, 2018 - 2030 (USD Million)
  • 93. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Operations, 2018 - 2030 (USD Million)
  • 94. Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Other Services, 2018 - 2030 (USD Million)
  • 95. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Consulting, 2018 - 2030 (USD Million)
  • 96. Global Biologics Regulatory Affairs Outsourcing, for Others Legal Representation, 2018 - 2030 (USD Million)
  • 97. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • 98. Global Biologics Regulatory Affairs Outsourcing, for Others Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • 99. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Submissions, 2018 - 2030 (USD Million)
  • 100. Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Operations, 2018 - 2030 (USD Million)
  • 101. Global Biologics Regulatory Affairs Outsourcing, for Others Other Services, 2018 - 2030 (USD Million)
  • 102. Regional Outlook, 2023 & 2030
  • 103. North America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 104. U.S. Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 105. Canada Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 106. Mexico Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 107. Europe Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 108. Germany Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 109. UK Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 110. France Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 111. Italy Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 112. Spain Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 113. Denmark Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 114. Sweden Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 115. Norway Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 116. Asia Pacific Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 117. Japan Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 118. China Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 119. India Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 120. Australia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 121. South Korea Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 122. Thailand Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 123. Latin America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 124. Brazil Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 125. Argentina Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 126. Middle East and Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 127. South Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 128. Saudi Arabia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 129. UAE Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 130. Kuwait Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)